269 related articles for article (PubMed ID: 22378094)
1. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery.
Jurczyńska J; Stepień T; Lawnicka H; Stepień H; Krupiński R; Kołomecki K; Kuzdak K; Komorowski J
Endokrynol Pol; 2009; 60(1):9-13. PubMed ID: 19224499
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
Kolomecki K; Stepien H; Bartos M; Kuzdak K
Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
6. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
Wieczór R; Wieczór AM; Gadomska G; Stankowska K; Fabisiak J; Suppan K; Pulkowski G; Budzyński J; Rość D
J Zhejiang Univ Sci B; 2016 Nov.; 17(11):842-849. PubMed ID: 27819131
[TBL] [Abstract][Full Text] [Related]
7. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
8. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejewska A; Robak T
Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
[TBL] [Abstract][Full Text] [Related]
10. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Wieczór R; Gadomska G; Ruszkowska-Ciastek B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
J Zhejiang Univ Sci B; 2015 Nov; 16(11):948-56. PubMed ID: 26537213
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
12. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
13. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
[TBL] [Abstract][Full Text] [Related]
14. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
Chang YT; Chang MC; Wei SC; Tien YW; Hsu C; Liang PC; Tsao PN; Jan IS; Wong JM
Pancreas; 2008 Aug; 37(2):145-50. PubMed ID: 18665074
[TBL] [Abstract][Full Text] [Related]
15. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.
Wada H; Satoh N; Kitaoka S; Ono K; Morimoto T; Kawamura T; Nakano T; Fujita M; Kita T; Shimatsu A; Hasegawa K
Atherosclerosis; 2010 Feb; 208(2):512-7. PubMed ID: 19695569
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours.
Kołomecki K; Stepień H; Narebski JM
Cytobios; 2000; 101(396):55-64. PubMed ID: 10697745
[TBL] [Abstract][Full Text] [Related]
17. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
19. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
20. VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms.
Gadomska G; Stankowska K; Boinska J; Ślusarz R; Tylicka M; Michalska M; Jachalska A; Rość D
Medicina (Kaunas); 2017; 53(1):34-39. PubMed ID: 28237691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
